

# Edward M Sellers

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2715163/edward-m-sellers-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

|                    |                          |                |                 |
|--------------------|--------------------------|----------------|-----------------|
| 225<br>papers      | 13,663<br>citations      | 65<br>h-index  | 108<br>g-index  |
| 230<br>ext. papers | 14,749<br>ext. citations | 6.8<br>avg, IF | 5.98<br>L-index |

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 225 | Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). <i>Addiction</i> , <b>1989</b> , 84, 1353-7   | 4.6  | 1148      |
| 224 | Binding of drugs to serum albumin (first of two parts). <i>New England Journal of Medicine</i> , <b>1976</b> , 294, 311-6   | 59.2 | 333       |
| 223 | Alcohol intoxication and withdrawal. <i>New England Journal of Medicine</i> , <b>1976</b> , 294, 757-62   | 59.2 | 316       |
| 222 | Withdrawal reaction after long-term therapeutic use of benzodiazepines. <i>New England Journal of Medicine</i> , <b>1986</b> , 315, 854-9   | 59.2 | 310       |
| 221 | Nicotine metabolism defect reduces smoking. <i>Nature</i> , <b>1998</b> , 393, 750  | 50.4 | 289       |
| 220 | Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. <i>Archives of General Psychiatry</i> , <b>2002</b> , 59, 851-8 |      | 282       |
| 219 | Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. <i>Pharmacogenetics and Genomics</i> , <b>2004</b> , 14, 615-26   |      | 244       |
| 218 | 5-HT and alcohol abuse. <i>Trends in Pharmacological Sciences</i> , <b>1992</b> , 13, 69-75   | 13.2 | 244       |
| 217 | Inhibition by fluoxetine of cytochrome P450 2D6 activity. <i>Clinical Pharmacology and Therapeutics</i> , <b>1993</b> , 53, 401-9   | 6.1  | 228       |
| 216 | Drug interactions with coumarin anticoagulants. 2. <i>New England Journal of Medicine</i> , <b>1971</b> , 285, 547-58   | 59.2 | 217       |
| 215 | The serotonin uptake inhibitor citalopram attenuates ethanol intake. <i>Clinical Pharmacology and Therapeutics</i> , <b>1987</b> , 41, 266-74   | 6.1  | 207       |
| 214 | Drug Interactions with Coumarin Anticoagulants. <i>New England Journal of Medicine</i> , <b>1971</b> , 285, 487-498   | 59.2 | 207       |
| 213 | Measurement issues in postpartum depression part 1: anxiety as a feature of postpartum depression. <i>Archives of Women's Mental Health</i> , <b>2003</b> , 6, 51-7   | 5    | 205       |
| 212 | Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1984</b> , 35, 374-81  | 6.1  | 204       |
| 211 | Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. <i>Molecular Pharmacology</i> , <b>2000</b> , 58, 747-55   | 4.3  | 203       |
| 210 | Inhibition of cytochromes P450 by antifungal imidazole derivatives. <i>Drug Metabolism and Disposition</i> , <b>2002</b> , 30, 314-8  | 4    | 202       |
| 209 | Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 77, 145-58  | 6.1  | 199       |

|     |   |      |     |
|-----|---|------|-----|
| 208 | Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1990</b> , 47, 490-8   | 6.1  | 187 |
| 207 | Drug therapy. Binding of drugs to serum albumin (second of two parts). <i>New England Journal of Medicine</i> , <b>1976</b> , 294, 526-31   | 59.2 | 176 |
| 206 | Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care. <i>Journal of Clinical Psychopharmacology</i> , <b>1981</b> , 1, 382-89  | 1.7  | 163 |
| 205 | Clinical efficacy of the 5-HT <sub>3</sub> antagonist ondansetron in alcohol abuse and dependence. <i>Alcoholism: Clinical and Experimental Research</i> , <b>1994</b> , 18, 879-85   | 3.7  | 152 |
| 204 | CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. <i>Clinical Pharmacology and Therapeutics</i> , <b>1993</b> , 54, 463-72  | 6.1  | 144 |
| 203 | Interactions of amphetamine analogs with human liver CYP2D6. <i>Biochemical Pharmacology</i> , <b>1997</b> , 53, 1605-12  | 6    | 139 |
| 202 | Inhibition of cytochrome P450 2A6 increases nicotine oral bioavailability and decreases smoking. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 68, 35-43  | 6.1  | 126 |
| 201 | Challenges in the development of prescription opioid abuse-deterrent formulations. <i>Clinical Journal of Pain</i> , <b>2007</b> , 23, 648-60   | 3.5  | 116 |
| 200 | An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. <i>Biochemical and Biophysical Research Communications</i> , <b>2002</b> , 290, 318-24   | 3.4  | 114 |
| 199 | Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 74, 437-47 | 6.1  | 112 |
| 198 | Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. <i>Pharmacogenetics and Genomics</i> , <b>1997</b> , 7, 375-9   |      | 111 |
| 197 | Mood changes during pregnancy and the postpartum period: development of a biopsychosocial model. <i>Acta Psychiatrica Scandinavica</i> , <b>2004</b> , 109, 457-66  | 6.5  | 110 |
| 196 | The ambiguity of adverse drug reactions. <i>European Journal of Clinical Pharmacology</i> , <b>1977</b> , 11, 75-8  | 2.8  | 109 |
| 195 | CYP2A6 genetic variation and potential consequences. <i>Advanced Drug Delivery Reviews</i> , <b>2002</b> , 54, 1245-58  | 18.5 | 107 |
| 194 | Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 163-71   | 3.2  | 106 |
| 193 | Drug therapy: Drugs to decrease alcohol consumption. <i>New England Journal of Medicine</i> , <b>1981</b> , 305, 1255-62  | 3.9  | 101 |
| 192 | Importance of protein binding for the interpretation of serum or plasma drug concentrations. <i>Journal of Clinical Pharmacology</i> , <b>1982</b> , 22, 259-63   | 2.9  | 101 |
| 191 | Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. <i>Annals of the New York Academy of Sciences</i> , <b>1971</b> , 179, 213-25  | 6.5  | 101 |

|     |   |      |     |
|-----|---|------|-----|
| 190 | Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU. <i>Intensive Care Medicine</i> , <b>2003</b> , 29, 2230-2238  | 14.5 | 100 |
| 189 | Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. <i>Clinical Pharmacology and Therapeutics</i> , <b>1970</b> , 11, 524-9  | 6.1  | 97  |
| 188 | Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. <i>Psychopharmacology</i> , <b>2006</b> , 186, 425-33   | 4.7  | 93  |
| 187 | Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. <i>Journal of Clinical Psychopharmacology</i> , <b>1995</b> , 15, 263-9   | 1.7  | 93  |
| 186 | Drug kinetics and alcohol ingestion. <i>Clinical Pharmacokinetics</i> , <b>1978</b> , 3, 440-52   | 6.2  | 90  |
| 185 | Protein binding and vascular activity of diazoxide. <i>New England Journal of Medicine</i> , <b>1969</b> , 281, 1141-5  | 59.2 | 90  |
| 184 | Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. <i>Pharmacogenetics and Genomics</i> , <b>2001</b> , 11, 477-87  |      | 87  |
| 183 | A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. <i>Journal of Psychopharmacology</i> , <b>2018</b> , 32, 1351-1361 | 4.6  | 86  |
| 182 | Potentialiation of warfarin-induced hypoprothrombinemia by chloral hydrate. <i>New England Journal of Medicine</i> , <b>1970</b> , 283, 827-31  | 59.2 | 85  |
| 181 | Effect of drugs influencing 5-HT function on ethanol drinking and feeding behaviour in rats: studies using a drinkometer system. <i>Neuroscience and Biobehavioral Reviews</i> , <b>1992</b> , 16, 535-52   | 9    | 84  |
| 180 | Interaction of chloral hydrate and ethanol in man. I. Metabolism. <i>Clinical Pharmacology and Therapeutics</i> , <b>1972</b> , 13, 37-49   | 6.1  | 83  |
| 179 | 3alpha-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period. <i>Gynecological Endocrinology</i> , <b>2005</b> , 21, 268-79  | 2.4  | 80  |
| 178 | Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. <i>Pharmacogenetics and Genomics</i> , <b>1998</b> , 8, 325-33   |      | 80  |
| 177 | Effect of the 5-HT <sub>3</sub> receptor antagonists, MDL72222 and ondansetron on morphine place conditioning. <i>Psychopharmacology</i> , <b>1992</b> , 106, 315-20  | 4.7  | 79  |
| 176 | From obesity to substance abuse: therapeutic opportunities for 5-HT <sub>2C</sub> receptor agonists. <i>Trends in Pharmacological Sciences</i> , <b>2013</b> , 34, 560-70   | 13.2 | 77  |
| 175 | Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. <i>Clinical Pharmacology and Therapeutics</i> , <b>1997</b> , 62, 334-47                                       | 6.1  | 76  |
| 174 | Antagonist-precipitated opioid withdrawal in rats: evidence for dissociations between physical and motivational signs. <i>Pharmacology Biochemistry and Behavior</i> , <b>1994</b> , 48, 1-8  | 3.9  | 74  |
| 173 | Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. <i>Journal of Clinical Pharmacology</i> , <b>2004</b> , 44, 1132-42  | 2.9  | 73  |

|     |   |     |    |
|-----|---|-----|----|
| 172 | NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. <i>Pharmacogenetics and Genomics</i> , <b>1998</b> , 8, 305-13 |     | 73 |
| 171 | Differential effects of viqualine on alcohol intake and other consummatory behaviors. <i>Clinical Pharmacology and Therapeutics</i> , <b>1989</b> , 46, 301-9   | 6.1 | 73 |
| 170 | Nicotine physical dependence and tolerance in the mouse following chronic oral administration. <i>Psychopharmacology</i> , <b>2005</b> , 178, 183-92  | 4.7 | 72 |
| 169 | Patterns of benzodiazepine abuse and dependence. <i>Addiction</i> , <b>1986</b> , 81, 87-94   | 4.6 | 72 |
| 168 | Effect of the 5-HT <sub>3</sub> antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. <i>Psychopharmacology</i> , <b>1995</b> , 117, 479-85         | 4.7 | 71 |
| 167 | Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective. <i>Clinical Pharmacokinetics</i> , <b>1986</b> , 11, 144-53  | 6.2 | 71 |
| 166 | Age- and gender-related differences in diazepam pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , <b>1979</b> , 19, 15-9  | 2.9 | 71 |
| 165 | Nonpharmacologic intervention in acute alcohol withdrawal. <i>Clinical Pharmacology and Therapeutics</i> , <b>1983</b> , 34, 214-9  | 6.1 | 70 |
| 164 | Clinical pharmacokinetics of non-opiate abused drugs. <i>Clinical Pharmacokinetics</i> , <b>1989</b> , 16, 1-26   | 6.2 | 69 |
| 163 | In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. <i>British Journal of Anaesthesia</i> , <b>1983</b> , 55, 985-9  | 5.4 | 69 |
| 162 | Diazepam actions and plasma concentrations following ethanol ingestion. <i>European Journal of Clinical Pharmacology</i> , <b>1977</b> , 11, 345-9  | 2.8 | 69 |
| 161 | Decreasing smoking behaviour and risk through CYP2A6 inhibition. <i>Drug Discovery Today</i> , <b>2003</b> , 8, 487-93  | 3.8 | 66 |
| 160 | Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. <i>Epilepsy and Behavior</i> , <b>2018</b> , 88, 162-171                      | 3.2 | 64 |
| 159 | Characteristics of dependent and nondependent regular users of codeine. <i>Journal of Clinical Psychopharmacology</i> , <b>1999</b> , 19, 367-72  | 1.7 | 63 |
| 158 | Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. <i>Human Mutation</i> , <b>2008</b> , 29, 679-88  | 4.7 | 62 |
| 157 | Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. <i>Drug and Alcohol Dependence</i> , <b>2007</b> , 89, 24-33                          | 4.9 | 61 |
| 156 | A Clinical Scale to Assess Benzodiazepine Withdrawal. <i>Journal of Clinical Psychopharmacology</i> , <b>1989</b> , 9, 412-416  | 1.7 | 61 |
| 155 | The NMDA antagonist dizocilpine (MK801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. <i>Life Sciences</i> , <b>1992</b> , 50, PL167-72                    | 6.8 | 60 |

|     |   |     |    |
|-----|---|-----|----|
| 154 | Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 459-67   | 1.7 | 58 |
| 153 | Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists. <i>Brain Research</i> , <b>1992</b> , 572, 208-15   | 3.7 | 57 |
| 152 | Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. <i>Molecular Pharmacology</i> , <b>2003</b> , 63, 96-104  | 4.3 | 56 |
| 151 | Low doses of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake. <i>Psychopharmacology</i> , <b>1994</b> , 115, 173-9   | 4.7 | 53 |
| 150 | Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. <i>Biochemical Pharmacology</i> , <b>2002</b> , 63, 2111-9  | 6   | 52 |
| 149 | Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2001</b> , 79, 841-847  | 2.4 | 52 |
| 148 | Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. <i>Clinical Drug Investigation</i> , <b>2009</b> , 29, 777-90 | 3.2 | 51 |
| 147 | The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. <i>Nicotine and Tobacco Research</i> , <b>2003</b> , 5, 891-9  | 4.9 | 51 |
| 146 | CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2006</b> , 15, 1812-9  | 4   | 50 |
| 145 | Research design strategies to evaluate the impact of formulations on abuse liability. <i>Drug and Alcohol Dependence</i> , <b>2006</b> , 83 Suppl 1, S52-62   | 4.9 | 50 |
| 144 | Objective determination of benzodiazepine use and abuse in alcoholics. <i>Addiction</i> , <b>1983</b> , 78, 429-35  | 4.6 | 50 |
| 143 | Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique. <i>Clinical Pharmacology and Therapeutics</i> , <b>1981</b> , 30, 71-6  | 6.1 | 49 |
| 142 | Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. <i>Journal of Women's Health and Gender-Based Medicine</i> , <b>2002</b> , 11, 147-53  |     | 48 |
| 141 | Chlordiazepoxide and oxazepam disposition in cirrhosis. <i>Clinical Pharmacology and Therapeutics</i> , <b>1979</b> , 26, 240-6   | 6.1 | 48 |
| 140 | A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. <i>Human Psychopharmacology</i> , <b>2011</b> , 26, 224-36   | 2.3 | 47 |
| 139 | Characterization of DSM-III-R criteria for uncomplicated alcohol withdrawal provides an empirical basis for DSM-IV. <i>Archives of General Psychiatry</i> , <b>1991</b> , 48, 442-7   |     | 47 |
| 138 | Effects of 5-HT3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal. <i>Psychopharmacology</i> , <b>1991</b> , 105, 322-8  | 4.7 | 47 |
| 137 | Clinical pharmacokinetics of chlordiazepoxide. <i>Clinical Pharmacokinetics</i> , <b>1978</b> , 3, 381-94   | 6.2 | 47 |

|     |  |     |    |
|-----|--|-----|----|
| 136 | Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. <i>Drug Metabolism and Disposition</i> , <b>2003</b> , 31, 768-72   | 4   | 46 |
| 135 | CYP2E1*1D regulatory polymorphism. <i>Pharmacogenetics and Genomics</i> , <b>2003</b> , 13, 321-328  |     | 46 |
| 134 | Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. <i>Journal of Clinical Pharmacology</i> , <b>2007</b> , 47, 1476-88          | 2.9 | 44 |
| 133 | The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. <i>Pharmacogenomics</i> , <b>2002</b> , 3, 185-99   | 2.6 | 44 |
| 132 | Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. <i>Pharmacogenetics and Genomics</i> , <b>2001</b> , 11, 85-94   |     | 44 |
| 131 | Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 55, 451-63  | 6.1 | 44 |
| 130 | Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. <i>Journal of Clinical Pharmacology</i> , <b>2014</b> , 54, 468-77 | 2.9 | 43 |
| 129 | Multiple drug use and psychiatric comorbidity in patients admitted to the hospital with severe benzodiazepine dependence. <i>Journal of Clinical Psychopharmacology</i> , <b>1996</b> , 16, 51-7   | 1.7 | 43 |
| 128 | Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. <i>Journal of Clinical Psychopharmacology</i> , <b>2000</b> , 20, 435-44   | 1.7 | 42 |
| 127 | Use of Remifentanyl in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent $\mu$ -Receptor Antagonist. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 242-9                            | 1.7 | 41 |
| 126 | Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. <i>Pain</i> , <b>2012</b> , 153, 2315-2324  | 8   | 41 |
| 125 | Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2003</b> , 306, 941-7                                    | 4.7 | 40 |
| 124 | Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. <i>Journal of Clinical Pharmacology</i> , <b>2005</b> , 45, 1413-21   | 2.9 | 40 |
| 123 | Influence of 5-HT <sub>3</sub> receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats. <i>Psychopharmacology</i> , <b>1994</b> , 114, 611-9  | 4.7 | 40 |
| 122 | CYP2D6 inhibition in patients treated with sertraline. <i>Journal of Clinical Psychopharmacology</i> , <b>1997</b> , 17, 102-6   | 1.7 | 40 |
| 121 | Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. <i>Journal of Clinical Psychopharmacology</i> , <b>1998</b> , 18, 332-7  | 1.7 | 40 |
| 120 | Interaction of warfarin stereoisomers with human albumin. <i>Pharmacological Research Communications</i> , <b>1975</b> , 7, 331-336  |     | 38 |
| 119 | Long-term codeine use is associated with depressive symptoms. <i>Journal of Clinical Psychopharmacology</i> , <b>1999</b> , 19, 373-6  | 1.7 | 38 |



|     |   |      |    |
|-----|---|------|----|
| 118 | Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. <i>Clinical Pharmacology and Therapeutics</i> , <b>1998</b> , 64, 378-83   | 6.1  | 36 |
| 117 | Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. <i>Epilepsy and Behavior</i> , <b>2010</b> , 18, 366-73  | 3.2  | 35 |
| 116 | A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. <i>Pharmacogenomics Journal</i> , <b>2009</b> , 9, 274-82   | 3.5  | 35 |
| 115 | Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. <i>Pharmacogenetics and Genomics</i> , <b>2005</b> , 15, 189-92   | 1.9  | 35 |
| 114 | Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome. <i>Recent Developments in Alcoholism: an Official Publication of the American Medical Society on Alcoholism, and the Research Society on Alcoholism, and the National Council on Alcoholism</i> , <b>1986</b> , 4, 265-81 |      | 35 |
| 113 | Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 396-405                                    | 1.7  | 34 |
| 112 | Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. <i>Journal of Clinical Psychopharmacology</i> , <b>2010</b> , 30, 25-33   | 1.7  | 34 |
| 111 | Mimicking gene defects to treat drug dependence. <i>Annals of the New York Academy of Sciences</i> , <b>2000</b> , 909, 233-46  | 6.5  | 34 |
| 110 | Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. <i>Journal of Clinical Psychopharmacology</i> , <b>1995</b> , 15, 117-24  | 1.7  | 34 |
| 109 | Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: a kinetic approach. <i>Clinical Pharmacology and Therapeutics</i> , <b>1979</b> , 26, 256-64   | 6.1  | 33 |
| 108 | Lack of interaction of buprenorphine with flunitrazepam metabolism. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 1164-6   | 11.9 | 32 |
| 107 | Influence of intravenous injection rate on protein binding and vascular activity of diazoxide. <i>Annals of the New York Academy of Sciences</i> , <b>1973</b> , 226, 319-32  | 6.5  | 32 |
| 106 | Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. <i>Biochemical Pharmacology</i> , <b>2001</b> , 62, 1025-36  | 6    | 31 |
| 105 | New CYP2A6 gene deletion and conversion variants in a population of Black African descent. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 189-98   | 2.6  | 30 |
| 104 | Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 192-9   | 6.1  | 30 |
| 103 | Binding of diazoxide and other benzothiadiazines to human albumin. <i>Biochemical Pharmacology</i> , <b>1974</b> , 23, 553-66   | 6    | 30 |
| 102 | Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 808-16   | 4.6  | 29 |
| 101 | A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. <i>Nicotine and Tobacco Research</i> , <b>1999</b> , 1 Suppl 2, S63-7; discussion S69-70   | 4.9  | 29 |



|     |   |     |    |
|-----|---|-----|----|
| 100 | Effects of low-dose opioids on cognitive dysfunction. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4342-3; author reply 4343-4   | 2.2 | 28 |
| 99  | Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. <i>Carcinogenesis</i> , <b>2007</b> , 28, 2139-42   | 4.6 | 28 |
| 98  | Triazolam and ethanol interaction: kinetic and dynamic consequences. <i>Clinical Pharmacology and Therapeutics</i> , <b>1985</b> , 37, 558-62   | 6.1 | 28 |
| 97  | Interaction of chloral hydrate and ethanol in man. II. Hemodynamics and performance. <i>Clinical Pharmacology and Therapeutics</i> , <b>1972</b> , 13, 50-8   | 6.1 | 28 |
| 96  | A controlled trial of ondansetron, a 5-HT <sub>3</sub> antagonist, in benzodiazepine discontinuation. <i>Journal of Clinical Psychopharmacology</i> , <b>1998</b> , 18, 121-31                                    | 1.7 | 26 |
| 95  | Comparative abuse liability of intravenously administered remifentanyl and fentanyl. <i>Journal of Clinical Psychopharmacology</i> , <b>2000</b> , 20, 597-606  | 1.7 | 26 |
| 94  | Acute kinetic and dynamic interactions of zimelidine with ethanol. <i>Clinical Pharmacology and Therapeutics</i> , <b>1984</b> , 36, 654-60   | 6.1 | 25 |
| 93  | The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. <i>Journal of Clinical Psychopharmacology</i> , <b>1998</b> , 18, 55-61                              | 1.7 | 25 |
| 92  | Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. <i>Journal of Clinical Psychopharmacology</i> , <b>1999</b> , 19, 472-5                                    | 1.7 | 25 |
| 91  | The CCKA receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol. <i>Brain Research</i> , <b>1994</b> , 640, 246-54 | 3.7 | 24 |
| 90  | Anxiolytics and sedative/hypnotics dependence. <i>Addiction</i> , <b>1991</b> , 86, 1647-52   | 4.6 | 24 |
| 89  | Drug deprivation and reinforcement by diazepam in a dependent population. <i>Psychopharmacology</i> , <b>1987</b> , 91, 154-60  | 4.7 | 24 |
| 88  | Intravascular factors affecting diazepam binding to human serum albumin. <i>Biochemical Pharmacology</i> , <b>1979</b> , 28, 3265-70  | 6   | 24 |
| 87  | Comparative metabolism of chloral hydrate and triclofos. <i>Journal of Clinical Pharmacology</i> , <b>1978</b> , 18, 457-61   | 2.9 | 24 |
| 86  | Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. <i>Neuropsychiatric Disease and Treatment</i> , <b>2014</b> , 10, 1161-74                               | 3.1 | 23 |
| 85  | Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>1997</b> , 22, 295-304             | 2.7 | 23 |
| 84  | Cytochrome P450 2D6 and treatment of codeine dependence. <i>Journal of Clinical Psychopharmacology</i> , <b>2000</b> , 20, 43-5   | 1.7 | 23 |
| 83  | Effect of 5-HT <sub>3</sub> receptor antagonists on the discriminative stimulus properties of morphine in rats. <i>Psychopharmacology</i> , <b>1993</b> , 112, 111-5  | 4.7 | 22 |

|    |   |     |    |
|----|---|-----|----|
| 82 | Survival after massive procainamide ingestion. <i>American Journal of Cardiology</i> , <b>1973</b> , 32, 727-30   | 3   | 22 |
| 81 | Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. <i>Journal of Opioid Management</i> , <b>2011</b> , 7, 179-92 <sup>9,8</sup>                                   | 2.8 | 22 |
| 80 | Human abuse liability evaluation of CNS stimulant drugs. <i>Neuropharmacology</i> , <b>2014</b> , 87, 81-90   | 5.5 | 21 |
| 79 | Oral Human Abuse Potential of Oxycodone DETERx (Xtampza ER). <i>Journal of Clinical Pharmacology</i> , <b>2017</b> , 57, 500-512  | 2.9 | 21 |
| 78 | Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. <i>European Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 481-4  | 2.8 | 21 |
| 77 | Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 326-9   | 1.7 | 21 |
| 76 | Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , <b>1999</b> , 54, 239-49                                 | 4.9 | 21 |
| 75 | Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. <i>Journal of Clinical Psychopharmacology</i> , <b>2003</b> , 23, 269-80   | 1.7 | 20 |
| 74 | Use of hair analysis for confirmation of self-reported cocaine use in users with negative urine tests. <i>Journal of Toxicology: Clinical Toxicology</i> , <b>2001</b> , 39, 361-6  |     | 20 |
| 73 | A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray. <i>Clinical Pharmacology in Drug Development</i> , <b>2013</b> , 2, 285-94                        | 2.3 | 19 |
| 72 | CYP2D6 phenotype and genotype in a Canadian Native Indian population. <i>Pharmacogenetics and Genomics</i> , <b>1997</b> , 7, 145-8   |     | 19 |
| 71 | Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. <i>Journal of Opioid Management</i> , <b>2014</b> , 10, 119-34  | 0.8 | 19 |
| 70 | Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. <i>Journal of Clinical Psychopharmacology</i> , <b>1998</b> , 18, 198-207   | 1.7 | 19 |
| 69 | Effect of metabolic blockade on the psychoactive effects of dextromethorphan. <i>Human Psychopharmacology</i> , <b>2010</b> , 25, 71-9  | 2.3 | 18 |
| 68 | Characteristics of Long-term Alprazolam Users in the Community. <i>Journal of Clinical Psychopharmacology</i> , <b>1992</b> , 12, 316-321   | 1.7 | 17 |
| 67 | Difficulties in assessing adverse drug reactions in clinical trials. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>1982</b> , 6, 651-7   | 5.5 | 17 |
| 66 | Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report. <i>Drug and Alcohol Dependence</i> , <b>2009</b> , 105 Suppl 1, S65-71  | 4.9 | 16 |
| 65 | The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. <i>Journal of Clinical Pharmacology</i> , <b>2007</b> , 47, 604-12 | 2.9 | 16 |

|    |  |     |    |
|----|--|-----|----|
| 64 | Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. <i>Drug Metabolism and Disposition</i> , <b>2002</b> , 30, 663-9  | 4   | 16 |
| 63 | Enalapril effects on alcohol intake and other consummatory behaviors in alcoholics. <i>Clinical Pharmacology and Therapeutics</i> , <b>1991</b> , 50, 96-106   | 6.1 | 16 |
| 62 | Relative abuse potential of opioid formulations in Canada: a structured field study. <i>Journal of Opioid Management</i> , <b>2006</b> , 2, 219-27   | 0.8 | 16 |
| 61 | Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. <i>Journal of Clinical Psychopharmacology</i> , <b>2016</b> , 36, 314-23                                | 1.7 | 15 |
| 60 | Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 1170-81 | 3.5 | 15 |
| 59 | Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum. <i>Journal of Pain Research</i> , <b>2013</b> , 6, 791-801  | 2.9 | 15 |
| 58 | Preliminary findings with the indirect 5-HT agonist dexfenfluramine on heroin discrimination and self-administration in rats. <i>Pharmacology Biochemistry and Behavior</i> , <b>1993</b> , 45, 963-6  | 3.9 | 15 |
| 57 | Blockade of morphine place conditioning by the CCKA receptor antagonist devazepide. <i>European Journal of Pharmacology</i> , <b>1991</b> , 197, 229-30  | 5.3 | 15 |
| 56 | Long-term benzodiazepine therapy does not result in brain abnormalities. <i>Journal of Clinical Psychopharmacology</i> , <b>2000</b> , 20, 2-6   | 1.7 | 15 |
| 55 | Studies with psychedelic drugs in human volunteers. <i>Neuropharmacology</i> , <b>2018</b> , 142, 116-134  | 5.5 | 15 |
| 54 | EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. <i>Psychopharmacology</i> , <b>2004</b> , 175, 382-8  | 4.7 | 14 |
| 53 | Ethanol interactions with serotonin uptake selective and non-selective antidepressants: Fluoxetine and amitriptyline. <i>Human Psychopharmacology</i> , <b>1989</b> , 4, 113-120   | 2.3 | 14 |
| 52 | The effect of propranolol on normal physiologic tremor. <i>Electroencephalography and Clinical Neurophysiology</i> , <b>1976</b> , 41, 310-3   |     | 14 |
| 51 | Addictive drugs: disposition, tolerance, and dependence interrelationships. <i>Drug Metabolism Reviews</i> , <b>1978</b> , 8, 5-11   | 7   | 14 |
| 50 | A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam. <i>Journal of Clinical Psychopharmacology</i> , <b>2000</b> , 20, 628-35  | 1.7 | 14 |
| 49 | Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study. <i>Journal of Clinical Pharmacology</i> , <b>2020</b> , 60, 495-504   | 2.9 | 14 |
| 48 | Psychedelic Drugs as Therapeutics: No Illusions About the Challenges. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 561-564   | 6.1 | 13 |
| 47 | The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential. <i>Drug and Alcohol Dependence</i> , <b>2010</b> , 112, 173-7   | 4.9 | 13 |

|    |  |     |    |
|----|--|-----|----|
| 46 | Brain Network Activation (BNA) reveals scopolamine-induced impairment of visual working memory. <i>Journal of Molecular Neuroscience</i> , <b>2014</b> , 54, 59-70   | 3.3 | 12 |
| 45 | Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 492-502 | 1.7 | 12 |
| 44 | Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32, 157-69  | 3.2 | 11 |
| 43 | Designer drugs that are potent inhibitors of CYP2D6. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 330-2   | 1.7 | 11 |
| 42 | Compliance among heavy alcohol users in clinical drug trials. <i>Journal of Substance Abuse</i> , <b>1988</b> , 1, 183-94  |     | 11 |
| 41 | Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. <i>CNS Drugs</i> , <b>2014</b> , 28, 361-72   | 6.7 | 10 |
| 40 | Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults. <i>Journal of Clinical Pharmacology</i> , <b>2006</b> , 46, 345-52   | 2.9 | 10 |
| 39 | Treatment of the barbiturate abstinence syndrome*. <i>Medical Journal of Australia</i> , <b>1986</b> , 145, 456-458  | 4   | 10 |
| 38 | An improved HPLC method for analysis of methamphetamine and its metabolites in plasma. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>1997</b> , 22, 427-32  | 2.7 | 9  |
| 37 | Phencyclidine ingestion: drug abuse and psychosis. <i>Substance Use and Misuse</i> , <b>1981</b> , 16, 749-58  |     | 9  |
| 36 | Defining the true therapeutics and clinical pharmacology curriculum in a Canadian medical school: implications for change. <i>Clinical Pharmacology and Therapeutics</i> , <b>1988</b> , 44, 629-33  | 6.1 | 8  |
| 35 | Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta) tablets in nondependent recreational opioid users. <i>Journal of Opioid Management</i> , <b>2012</b> , 8, 315-27                         | 0.8 | 8  |
| 34 | Benzodiazepines as Drugs of Abuse and Dependence <b>1986</b> , 53-126  |     | 8  |
| 33 | Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. <i>Pain Physician</i> , <b>2010</b> , 13, 561-73   | 1.8 | 8  |
| 32 | . <i>Journal of Clinical Psychopharmacology</i> , <b>2003</b> , 23, 269-280  | 1.7 | 7  |
| 31 | A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32, e1-15   | 3.2 | 6  |
| 30 | Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent. <i>Nicotine and Tobacco Research</i> , <b>2008</b> , 10, 1319-25  | 4.9 | 6  |
| 29 | Clinical detection and assessment of drug induced neurotoxicity. <i>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</i> , <b>1981</b> , 5, 427-34   |     | 6  |

|    |   |     |   |
|----|---|-----|---|
| 28 | Cognitive toxicity of drugs used in the elderly. <i>Dialogues in Clinical Neuroscience</i> , <b>2001</b> , 3, 181-90  | 5.7 | 6 |
| 27 | Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 640241   | 5.6 | 6 |
| 26 | Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping. <i>Journal of Clinical Pharmacology</i> , <b>2004</b> , 44, 966-73  | 2.9 | 5 |
| 25 | A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32, e1-e15   | 3.2 | 5 |
| 24 | Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 675-683 | 1.7 | 4 |
| 23 | The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond. <i>Pharmaceutical Medicine</i> , <b>2014</b> , 28, 317-327   | 2.3 | 4 |
| 22 | Efficacy of Dexfenfluramine in the Treatment of Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2000</b> , 24, 1534-1541   | 3.7 | 4 |
| 21 | Effect of dexfenfluramine on saccharin drinking: behavioural and pharmacological studies. <i>Pharmacology Biochemistry and Behavior</i> , <b>1994</b> , 47, 307-15  | 3.9 | 4 |
| 20 | Drug metabolism and interactions in abuse liability assessment. <i>Addiction</i> , <b>1991</b> , 86, 1607-14  | 4.6 | 4 |
| 19 | Deconstructing Designer Drugs. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 101, 167-169   | 6.1 | 3 |
| 18 | Serotonin Uptake Inhibitors Attenuate Ethanol Intake in Humans. <i>Australian Drug and Alcohol Review</i> , <b>1988</b> , 7, 109-112  |     | 3 |
| 17 | The nature and etiology of normal and alcohol withdrawal tremor. <i>IEEE Transactions on Biomedical Engineering</i> , <b>1979</b> , 26, 3-10  | 5   | 3 |
| 16 | Age- and sex-related differences in patterns of drug overdose and abuse. <i>Social Science &amp; Medicine Part E, Medical Psychology</i> , <b>1981</b> , 15, 275-82   |     | 3 |
| 15 | Drug-plasma protein binding in Kutchin Athapaskan indians. <i>Clinical Pharmacology and Therapeutics</i> , <b>1982</b> , 32, 436-41   | 6.1 | 2 |
| 14 | 5-HT and 5-HT receptors as potential targets for the treatment of nicotine use and dependence. <i>Progress in Brain Research</i> , <b>2021</b> , 259, 229-263   | 2.9 | 2 |
| 13 | Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 2: Optimizing the Design of Human Abuse Potential Studies. <i>Journal of Clinical Psychopharmacology</i> , <b>2018</b> , 38, 113-118   | 1.7 | 2 |
| 12 | Categorization of Abuse Potential-Related Adverse Events. <i>Clinical Pharmacology in Drug Development</i> , <b>2018</b> , 7, 569-574   | 2.3 | 1 |
| 11 | Pharmacotherapy of Alcohol Dependence: Improving Translation from the Bench to the Clinic <b>2008</b> , 91-178  |     | 1 |

- 10 Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 1: Regulatory Context and Risk Management. *Journal of Clinical Psychopharmacology*, **2018**, 38, 11-18 1.7 1
- 9 Pharmacotherapy of alcohol and drug problems. *Drug and Alcohol Review*, **1991**, 10, 215-24 3.2 0
- 8 Partial agonist properties and toxicity of oral oxilorphan. *Journal of Clinical Pharmacology*, **1976**, 16, 183-7 2.9 0
- 7 Identification of Optimal Measures of Human Abuse Potential: A Post Hoc Assessment of 19 Studies. *Journal of Clinical Psychopharmacology*, **2020**, 40, 568-578 1.7 0
- 6 Claudio A. Naranjo, MD (1945-2014). *Clinical Pharmacology and Therapeutics*, **2015**, 97, 14-5 6.1
- 5 Neurosteroids: A New Regulatory Function in the Nervous System. *Behavioural Neurology*, **1999**, 11, 261-3 262
- 4 A Reply to Dr Andrew Johns. *Addiction*, **1988**, 83, 1116-1117 4.6
- 3 Clinical pharmacology in Canada. *Clinical Pharmacology and Therapeutics*, **1974**, 16, 554-64 6.1
- 2 Treatment of the Acute Alcohol Withdrawal State: A Comparison of Four Drugs. *Alcohol Health and Research World*, **1995**, 19, 34-35
- 1 Modifying the Metabolism of Nicotine as a Therapeutic Strategy. *Novartis Foundation Symposium*, 235-248